These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 6092492)

  • 21. Antigenic analysis of the saccharide moiety of the lipooligosaccharide of Bordetella pertussis.
    Brodeur BR; Martin D; Hamel J; Shahin RD; Laferrière C
    Springer Semin Immunopathol; 1993; 15(2-3):205-15. PubMed ID: 8256198
    [No Abstract]   [Full Text] [Related]  

  • 22. Protective effects of in vivo-expressed autotransporters against Bordetella pertussis infection.
    Suzuki K; Shinzawa N; Ishigaki K; Nakamura K; Abe H; Fukui-Miyazaki A; Ikuta K; Horiguchi Y
    Microbiol Immunol; 2017 Sep; 61(9):371-379. PubMed ID: 28752940
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pertussis antibodies in vaccinated children.
    Preston NW
    Lancet; 1983 Nov; 2(8360):1197. PubMed ID: 6139553
    [No Abstract]   [Full Text] [Related]  

  • 24. Protective effects of vaccines against Bordetella parapertussis in a mouse intranasal challenge model.
    Komatsu E; Yamaguchi F; Eguchi M; Watanabe M
    Vaccine; 2010 Jun; 28(27):4362-8. PubMed ID: 20438876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel intranasal pertussis vaccine based on bacterium-like particles as a mucosal adjuvant.
    Shi W; Kou Y; Jiang H; Gao F; Kong W; Su W; Xu F; Jiang C
    Immunol Lett; 2018 Jun; 198():26-32. PubMed ID: 29601940
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effect of infectious diseases on levels of pertussis antibodies in children vaccinated against pertussis].
    Adonajlo A; Mazurowska-Magdzik M; Pstragowska W; Dadak M
    Przegl Epidemiol; 1975; 29(3):321-6. PubMed ID: 170650
    [No Abstract]   [Full Text] [Related]  

  • 27. Modulation of Bordetella pertussis infection with monoclonal antibodies to pertussis toxin.
    Halperin SA; Issekutz TB; Kasina A
    J Infect Dis; 1991 Feb; 163(2):355-61. PubMed ID: 1703192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity and protective efficacy of a newly developed tri-component diphtheria, tetanus, and acellular pertussis vaccine in a murine model.
    Huh DH; Han SB; Shin HJ; Ahn DH; Choi GS; Kang KR; Kim BR; Kang JH
    J Microbiol Immunol Infect; 2018 Dec; 51(6):732-739. PubMed ID: 28720318
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis.
    Knight JB; Huang YY; Halperin SA; Anderson R; Morris A; Macmillan A; Jones T; Burt DS; Van Nest G; Lee SF
    Clin Exp Immunol; 2006 Jun; 144(3):543-51. PubMed ID: 16734625
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjuvant effects of adenylate cyclase toxin of Bordetella pertussis after intranasal immunisation of mice.
    Orr B; Douce G; Baillie S; Parton R; Coote J
    Vaccine; 2007 Jan; 25(1):64-71. PubMed ID: 16916566
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term immunity against pertussis induced by a single nasal administration of live attenuated B. pertussis BPZE1.
    Feunou PF; Kammoun H; Debrie AS; Mielcarek N; Locht C
    Vaccine; 2010 Oct; 28(43):7047-53. PubMed ID: 20708998
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protective Role of Passively Transferred Maternal Cytokines against Bordetella pertussis Infection in Newborn Piglets.
    Elahi S; Thompson DR; Van Kessel J; Babiuk LA; Gerdts V
    Infect Immun; 2017 Apr; 85(4):. PubMed ID: 28167667
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Specific anti-Bordetella pertussis activities in human blood examined by enzyme-linked immunoassay and biological assay.
    Marley PB; Wilson JV; Habel H; Blaskett A
    Dev Biol Stand; 1985; 61():341-52. PubMed ID: 2872123
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Aerosol inoculation of Bordetella pertussis in mice].
    Sato Y; Arai H
    Nihon Saikingaku Zasshi; 1975 Jan; 30(1):198. PubMed ID: 175185
    [No Abstract]   [Full Text] [Related]  

  • 35. Immunogenicity of acellular pertussis vaccines using two vaccines for primary immunization.
    von König CH; Herden P; Palitzsch D; Schneeweiss B; Bier N
    Pediatr Infect Dis J; 2000 Aug; 19(8):757-9. PubMed ID: 10959748
    [No Abstract]   [Full Text] [Related]  

  • 36. Passive acquisition of protective antibodies reactive with Bordetella pertussis in newborns via placental transfer and breast-feeding.
    Quinello C; Quintilio W; Carneiro-Sampaio M; Palmeira P
    Scand J Immunol; 2010 Jul; 72(1):66-73. PubMed ID: 20591078
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Antigens of Bordetella pertussis and their repercussion in immunization programs against whooping cough].
    Casal Lombos J
    Rev Sanid Hig Publica (Madr); 1971 May; 45(5):575-87. PubMed ID: 4330706
    [No Abstract]   [Full Text] [Related]  

  • 38. Attenuated Bordetella pertussis: new live vaccines for intranasal immunisation.
    Mielcarek N; Debrie AS; Raze D; Quatannens J; Engle J; Goldman WE; Locht C
    Vaccine; 2006 Apr; 24 Suppl 2():S2-54-5. PubMed ID: 16823926
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity and protective efficacy of recombinant iron superoxide dismutase protein from Bordetella pertussis in mice models.
    Yılmaz Ç; Apak A; Özcengiz E; Özcengiz G
    Microbiol Immunol; 2016 Nov; 60(11):717-724. PubMed ID: 27761933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protocol for aerosolization challenge of mice with Bordetella pertussis.
    Bitzer G; Weaver K; Barbier M; Damron FH
    STAR Protoc; 2023 Mar; 4(1):101979. PubMed ID: 36598856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.